Skip to main content
Premium Trial:

Request an Annual Quote

UBS Downgrades Affymetrix Stock, Raises Target Price

NEW YORK, Jan. 31 (GenomeWeb News) - UBS Warburg has downgraded shares in Affymetrix to a "neutral" rating from a "buy" rating, CBS MarketWatch reported today.

According to MarketWatch, UBS said Affymetrix's stock trades at a "significant, and in our opinion well deserved, premium" to its peers and is now fairly priced. UBS also raised its price target for the stock to $47 per share from $43 per share, MarketWatch said.


Affy last week reported a surge in fourth-quarter revenue and increases net earnings.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.